The use of artificial intelligence (AI) in the pharmaceutical sector is transforming drug discovery, development, and regulatory approval processes, creating significant opportunities for the emerging techbio industry. According to a report by Tecknoworks, the global AI in pharmaceuticals market was valued at $1.8 billion in 2023 and is expected to grow substantially to $13.1 billion by 2034, representing a compound annual growth rate (CAGR) of 18.8% between 2024 and 2034.
The company we are profiling today is Caris Life Sciences, Inc. (CAI), a patient-centric AI TechBio company that uses molecular data and artificial intelligence/machine learning algorithms to advance precision medicine, with a primary focus on oncology and services for clinical, academic, and biopharma markets.
For comments and feedback: editorial@rttnews.com